Click the title above for a link to open the Pharmaceutical Executive November 2024 issue in an interactive PDF format.
Pharmaceutical Executive: November 2024
Developments in the world of artificial intelligence continue to accelerate at a rapid pace. Our November issue of Pharmaceutical Executive explores a few of those that are starting to deliver measurable gains for the industry.
A look at one biotech’s mission to map the immune system using artificial intelligence—and how its growth as a Big Pharma partner could help unlock the potential of next-generation cancer treatments.
Ann Beliën, PhD, founder and CEO of Rejuvenate Biomed, discusses how AI is being used to find new ways to treat age-related conditions.
Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.
Why tapping the value generated for the next set of therapies is critical.
Decisions and strategies related to remote work, AI, and DE&I are especially evolving.
Pharma looks to take advantage of expanded access programs across Asia-Pacific region.
The sector's XBI is up 15% year-to-date; rate cuts, election outcome, and M&A are viewed as tailwinds.
Pharma companies are facing a higher number of incredibly destructive cyber-threats than ever before.
